3 results on '"Yuti, Pornpimon"'
Search Results
2. Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.
- Author
-
Yuti, Pornpimon, Wutti-in, Yupanun, Sawasdee, Nunghathai, Kongkhla, Katesara, Phanthaphol, Nattaporn, Choomee, Kornkan, Chieochansin, Thaweesak, Panya, Aussara, Junking, Mutita, Yenchitsomanus, Pa-thai, and Sujjitjoon, Jatuporn
- Subjects
- *
PROGRAMMED death-ligand 1 , *CHIMERIC antigen receptors , *B cells , *MONOCLONAL antibodies , *T cell receptors , *PROGRAMMED cell death 1 receptors , *T cells , *B cell lymphoma , *CELL receptors - Abstract
[Display omitted] • Anti-CD19-CAR5-T cells exerted more effective cytotoxicity than anti-CD19-CAR4-T cells at a low effector-to-target ratio. • Cytotoxicity of anti-CD19-CAR4-T cells was inhibited by upregulations of PD-1 on CAR-T cells and PD-L1 on the target cancer cells. • The secreted anti-PD-L1 scFv from anti-CD19-CAR5-T cells could restore the cytotoxic effect of anti-CD19-CAR4-T cells. • The secreted anti-PD-L1 scFv promoted self-proliferation of anti-CD19-CAR5-T cells. • PD-L1 blockade by anti-PD-L1 scFv secreted from CAR5-T cells is a feasible strategy to improve CAR-T antitumor efficiency. Adoptive T cell therapy using second-generation anti-CD19 chimeric antigen receptor T cells (anti-CD19-CAR2-T) induced complete remission in many heavily pretreated patients with B cell acute lymphoblastic leukemia (B-ALL) or diffuse large B cell lymphoma (DLBCL). However, poor clinical efficacy was observed in treating aggressive B cell lymphomas (BCL). The limited T cell function was reported by programmed cell death protein 1 ligand (PD-L1) expressed on BCL cells bound to the PD-1 receptor on T cells. To overcome this problem, we generated anti-CD19-CAR4-T cells secreting anti-PD-L1 single-chain variable fragment (scFv), namely anti-CD19-CAR5-T cells, and evaluated their functions in vitro. Both anti-CD19-CAR-T cells contain an anti-CD19 scFv derived from a monoclonal antibody, FMC63, linked to CD28/4-1BB/CD27/CD3ζ. The secreting anti-PD-L1 scFv is derived from atezolizumab. Our results showed that secreted anti-PD-L1 scFv could bind to PD-L1 and block the binding of anti-PD-L1 monoclonal antibodies on PD-L1high tumor cells. Anti-CD19-CAR4-T and anti-CD19-CAR5-T cells efficiently killed CD19+ target tumor cells in two-dimensional (2D) and three-dimensional (3D) co-culture systems. However, anti-CD19-CAR5-T cells demonstrated superior proliferative ability. Interestingly, at a low effector (E) to target (T) ratio of 0.5:1, anti-CD19-CAR5-T cells showed higher cytotoxicity against CD19+/PD-L1high cells compared to that of anti-CD19-CAR4-T cells. The cytotoxicity of anti-CD19-CAR4-T cells against CD19+/PD-L1high could be restored by adding anti-PD-L1 scFv. Our findings demonstrate the combination antitumor efficiency of anti-CD19-CAR4-T cells and anti-PD-L1 scFv against CD19+/PD-L1high tumors. As such, anti-CD19-CAR5-T cells should be further investigated in vivo antitumor efficiency and clinical trials as a treatment for aggressive B cell lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.
- Author
-
Suwanchiwasiri, Kwanpirom, Phanthaphol, Nattaporn, Somboonpatarakun, Chalermchai, Yuti, Pornpimon, Sujjitjoon, Jatuporn, Luangwattananun, Piriya, Maher, John, Yenchitsomanus, Pa‑thai, and Junking, Mutita
- Subjects
- *
T cells , *INTEGRINS , *ANTINEOPLASTIC agents , *CHOLANGIOCARCINOMA , *IMMUNOLOGIC memory - Abstract
Advanced cholangiocarcinoma (CCA) presents a clinical challenge due to limited treatment options, necessitating exploration of innovative therapeutic approaches. Bispecific T cell engager (BTE)-armed T cell therapy shows promise in hematological and solid malignancies, offering potential advantages in safety over continuous BTE infusion. In this context, we developed a novel BTE, targeting CD3 on T cells and integrin αvβ6, an antigen elevated in various epithelial malignancies, on cancer cells. The novel BTE was generated by fusing an integrin αvβ6-binding peptide (A20) to an anti-CD3 (OKT3) single-chain variable fragment (scFv) through a G 4 S peptide linker (A20/αCD3 BTE). T cells were then armed with A20/αCD3 BTE (A20/αCD3-armed T cells) and assessed for antitumor activity. Our results highlight the specific binding of A20/αCD3 BTE to CD3 on T cells and integrin αvβ6 on target cells, effectively redirecting T cells towards these targets. After co-culture, A20/αCD3-armed T cells exhibited significantly heightened cytotoxicity against integrin αvβ6-expressing target cells compared to unarmed T cells in both KKU-213A cells and A375.β6 cells. Moreover, in a five-day co-culture, A20/αCD3-armed T cells demonstrated superior cytotoxicity against KKU-213A spheroids compared to unarmed T cells. Importantly, A20/αCD3-armed T cells exhibited an increased proportion of the effector memory T cell (Tem) subset, upregulation of T cell activation markers, enhanced T cell proliferation, and increased cytolytic molecule/cytokine production, when compared to unarmed T cells in an integrin αvβ6-dependent manner. These findings support the potential of A20/αCD3-armed T cells as a novel therapeutic approach for integrin αvβ6-expressing cancers. [Display omitted] • A20/αCD3 BTE targets both CD3 on T cells and integrin αvβ6 on cancer cells. • A20/αCD3-armed T cells exhibit higher antitumor activity compared to unarmed T cells. • A20/αCD3 BTE enhances T cell activation, proliferation, and cytokine secretion. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.